GSK plc (NYSE:GSK) Stock Position Lifted by EverSource Wealth Advisors LLC

EverSource Wealth Advisors LLC grew its position in GSK plc (NYSE:GSK) by 83.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,189 shares of the pharmaceutical company’s stock after acquiring an additional 1,902 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in GSK were worth $142,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Dorsey & Whitney Trust CO LLC lifted its holdings in GSK by 2.5% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company’s stock valued at $389,000 after acquiring an additional 278 shares during the last quarter. Sunbelt Securities Inc. lifted its stake in GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares during the last quarter. Rehmann Capital Advisory Group boosted its holdings in GSK by 6.3% during the third quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock worth $232,000 after buying an additional 332 shares in the last quarter. GC Wealth Management RIA LLC grew its position in GSK by 2.6% in the fourth quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company’s stock worth $474,000 after buying an additional 353 shares during the last quarter. Finally, Jacobi Capital Management LLC increased its holdings in shares of GSK by 3.9% in the fourth quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company’s stock valued at $352,000 after buying an additional 389 shares in the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Stock Performance

Shares of GSK stock opened at $40.30 on Tuesday. The stock has a market cap of $83.53 billion, a PE ratio of 25.35, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.93. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The business has a fifty day simple moving average of $36.18 and a 200-day simple moving average of $36.99.

GSK (NYSE:GSK) last released its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, sell-side analysts anticipate that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be given a $0.3932 dividend. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a yield of 3.90%. GSK’s dividend payout ratio is presently 98.74%.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Morgan Stanley started coverage on GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Seven equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.